Talk:Turoctocog alfa

This is the talk page for discussing improvements to the Turoctocog alfa article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Turoctocog alfa.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Route of administration?

Isn't the route of administration subcutaneous injection rather than intravenous infusion? — Preceding unsigned comment added by 190.236.204.121 (talk) 05:33, 10 August 2020 (UTC)[reply]

Per https://www.drugs.com/monograph/antihemophilic-factor-recombinant-pegylated-aucl.html, it's "For intravenous use after reconstitution only … Infuse antihemophilic factor (recombinant), PEGylated-aucl intravenously over a period of 1 to 15 minutes". The EMA says the same at https://www.ema.europa.eu/en/documents/product-information/novoeight-epar-product-information_en.pdf: "The recommended infusion rate for NovoEight is 1–2 ml/min". Hope that helps. --ἀνυπόδητος (talk) 08:57, 10 August 2020 (UTC)[reply]